By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.

New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.

King’s College London and Medicines Discovery Catapult have secured £400,000 from The Brain Tumour Charity to fast-track a new drug delivery approach for glioblastoma, the most aggressive brain cancer. The project will support preclinical studies to move potential treatments closer to patients.

Penn engineers have built an AI model that creates new antibiotics – and early tests show some work as well as existing approved drugs.

Northwestern University researchers have created DNA-coated nanoparticles that deliver CRISPR into cells three times more effectively while reducing toxicity. The advance could overcome one of the biggest barriers to gene-editing therapies.

Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.

Researchers have tested a new cancer drug in pet cats with head and neck squamous cell carcinoma – a disease notoriously hard to treat. The trial showed the therapy controlled cancer in 35 percent of cats with minimal side effects – and it could help to treat humans too.

A small subset of newborn liver cells – known as clonogenic hepatocytes – drives over 90 percent of adult liver growth. New research shows how targeting these cells early could improve the effectiveness and durability of paediatric gene therapies.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.

Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.

Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.